ClinicalTrials.gg
CompletedNCT04285515Updated Mar 19, 2025Results posted

Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder

A Phase 3 interventional study of Lumateperone and Placebos in Bipolar Depression and Major Depressive Disorder, sponsored by Intra-Cellular Therapies, Inc.. Completed at 42 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-03-19.

Sponsored by Intra-Cellular Therapies, Inc. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
488
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies in Bipolar Disorder by Johnson & Johnson — 2 open to participants now, 2 under way, 2 of them phase 3. Bipolar Disorder · Johnson & Johnson.

Enrollment
7th of 36
488 · median 300
Started
2020
the only one that year
Phase 3
28 of 39
2 open now
Registered
34th of 39
by date

Among the 39 studies in Bipolar Disorder by Johnson & Johnson, this one is the 7th largest by enrollment of the 36 interventional ones that give a count, is the only one that started in 2020, is one of 28 in phase 3, and was the 34th registered.

Bipolar Disorder

1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

2 of the 39 studies in Bipolar Disorder by Johnson & Johnson are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Bipolar Disorder by Johnson & Johnson, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of lumateperone monotherapy in the treatment of patients with major depressive episodes associated with Bipolar I or Bipolar II Disorder (Bipolar Depression) or major depressive disorder (MDD) who also meet the Diagnostic and Statistical Manual of Mental Disorder, 5th Edition (DSM-5) criteria for mixed-features. The study consists of a Screening Period, a Double-blind Treatment Period, and a Safety Follow-up Period.

03

Conditions studied

  • Bipolar Depression
  • Major Depressive Disorder

Keywords

  • Mixed Features
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Major Inclusion Criteria:

  • Male or female subjects of any race, ages 18-75 inclusive
  • Meets the Diagnostic and Statistical Manual of Mental Disorder, 5th Edition (DSM 5) criteria for Bipolar I or Bipolar II Disorder or MDD
  • The start of the current major depressive episode is at least 2 weeks but no more than 6 months prior to the Screening (Visit 1)
  • Has at least moderate severity of illness, as measured by a rater-administered MADRS total score ≥ 24 and corresponding to a CGI S score of ≥ 4 at Screening (Visit 1) and Baseline (Visit 2)
  • The patient meets the criteria for mixed-features specific to the Bipolar I or II diagnosis or MDD diagnosis
  • Current major depressive episode is causing distress or impairment in social, occupational, or other important areas of functioning
  • Able to provide written

Major Exclusion Criteria:

  • Any female subject who is pregnant or breast-feeding
  • Any subject judged to be medically inappropriate for study participation
  • The patient has a significant risk for suicidal behavior
  • The patient presents with a lifetime history of epilepsy, seizure or convulsion, or electroencephalogram with clinically significant abnormalities, delirium, dementia, amnestic, or other cognitive disorder or significant brain trauma
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
488 participants (actual)

Study arms

  • Experimental
    Lumateperone 42mg

    Lumateperone 42mg administered once daily in the evening

    Drug: Lumateperone

  • Placebo comparator
    Placebo

    Matching placebo administered once daily in the evening

    Drug: Placebos

Interventions

  • Lumateperone 42mg oral capsule

  • DrugPlacebos

    Placebo oral capsule

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score

    The Montgomery-Åsberg Depression Rating Scale is a clinician-rated 10 item scale to assess depressive symptoms. Each item is rated on a 7-point scale from 0-6. The total score ranges from 0 to 60 with a higher score indicating increased severity of depressive symptoms.

    Time frame: Day 43

Secondary outcomes

  1. Clinical From Baseline in Clinical Global Impression Scale - Severity (CGI-S)

    The Clinical Global Impression Scale-Severity is a clinician-rated scale to assess a patient's overall mental health. The scale ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).

    Time frame: Day 43

07

Results

Posted Mar 19, 2025

Participant flow

Participant flow — Overall Study
MilestoneLumateperone 42mgPlacebo
Started243245
Completed211217
Not completed3228

Outcome measures

PrimaryChange From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score

The Montgomery-Åsberg Depression Rating Scale is a clinician-rated 10 item scale to assess depressive symptoms. Each item is rated on a 7-point scale from 0-6. The total score ranges from 0 to 60 with a higher score indicating increased severity of depressive symptoms.

Time frame:
Day 43
Reported as:
Least squares mean · score on a scale
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
score on a scaleLumateperone 42mgPlacebo
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score-18.1 ± 0.71-12.4 ± 0.70
Statistical analysis
  • Lumateperone 42mg vs Placebo · Mixed Effects Model for Repeated Measure · p = <0.0001 · Least squares mean difference: -5.7 · 95% CI -7.60 to -3.84
PrimaryChange From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score

The Montgomery-Åsberg Depression Rating Scale is a clinician-rated 10 item scale to assess depressive symptoms. Each item is rated on a 7-point scale from 0-6. The total score ranges from 0 to 60 with a higher score indicating increased severity of depressive symptoms.

Time frame:
Day 43
Reported as:
Least squares mean · score on a scale
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
score on a scaleLumateperone 42mgPlacebo
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score-17.7 ± 1.00-12.0 ± 0.96
Statistical analysis
  • Lumateperone 42mg vs Placebo · Mixed Effects Model for Repeated Measure · p = <0.0001 · Least squares mean difference: -5.7 · 95% CI -8.29 to -3.05
PrimaryChange From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score

The Montgomery-Åsberg Depression Rating Scale is a clinician-rated 10 item scale to assess depressive symptoms. Each item is rated on a 7-point scale from 0-6. The total score ranges from 0 to 60 with a higher score indicating increased severity of depressive symptoms.

Time frame:
Day 43
Reported as:
Least squares mean · score on a scale
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
score on a scaleLumateperone 42mgPlacebo
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score-18.2 ± 0.95-12.2 ± 0.96
Statistical analysis
  • Lumateperone 42mg vs Placebo · Mixed Effects Model for Repeated Measure · p = <0.0001 · Least squares mean difference: -5.9 · 95% CI -8.61 to -3.29
PrimaryChange From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score

The Montgomery-Åsberg Depression Rating Scale is a clinician-rated 10 item scale to assess depressive symptoms. Each item is rated on a 7-point scale from 0-6. The total score ranges from 0 to 60 with a higher score indicating increased severity of depressive symptoms.

Time frame:
Day 43
Reported as:
Least squares mean · score on a scale
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
score on a scaleLumateperone 42mgPlacebo
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score-17.7 ± 0.64-12.1 ± 0.63
Statistical analysis
  • Lumateperone 42mg vs Placebo · Mixed Effects Model for Repeated Measure · p = <0.0001 · Least squares mean difference: -5.6 · 95% CI -7.25 to -3.88
SecondaryClinical From Baseline in Clinical Global Impression Scale - Severity (CGI-S)

The Clinical Global Impression Scale-Severity is a clinician-rated scale to assess a patient's overall mental health. The scale ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).

Time frame:
Day 43
Reported as:
Least squares mean · score on a scale
Clinical From Baseline in Clinical Global Impression Scale - Severity (CGI-S)
score on a scaleLumateperone 42mgPlacebo
Clinical From Baseline in Clinical Global Impression Scale - Severity (CGI-S)-1.8 ± 0.08-1.2 ± 0.08
Statistical analysis
  • Lumateperone 42mg vs Placebo · Mixed Effects Model of Repeated Measure · p = <0.0001 · Least squares mean difference: -0.6 · 95% CI -0.81 to -0.39
SecondaryClinical From Baseline in Clinical Global Impression Scale - Severity (CGI-S)

The Clinical Global Impression Scale-Severity is a clinician-rated scale to assess a patient's overall mental health. The scale ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).

Time frame:
Day 43
Reported as:
Least squares mean · score on a scale
Clinical From Baseline in Clinical Global Impression Scale - Severity (CGI-S)
score on a scaleLumateperone 42mgPlacebo
Clinical From Baseline in Clinical Global Impression Scale - Severity (CGI-S)-1.8 ± 0.11-1.2 ± 0.11
Statistical analysis
  • Lumateperone 42mg vs Placebo · Mixed Effects Model for Repeated Measure · p = <0.0001 · Least squares mean difference: -0.6 · 95% CI -0.91 to -0.31
SecondaryClinical From Baseline in Clinical Global Impression Scale - Severity (CGI-S)

The Clinical Global Impression Scale-Severity is a clinician-rated scale to assess a patient's overall mental health. The scale ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).

Time frame:
Day 43
Reported as:
Least squares mean · score on a scale
Clinical From Baseline in Clinical Global Impression Scale - Severity (CGI-S)
score on a scaleLumateperone 42mgPlacebo
Clinical From Baseline in Clinical Global Impression Scale - Severity (CGI-S)-1.7 ± 0.11-1.1 ± 0.11
Statistical analysis
  • Lumateperone 42mg vs Placebo · Mixed Effects Model for Repeated Measure · p = 0.0003 · Least squares mean difference: -0.6 · 95% CI -0.89 to -0.27
SecondaryClinical From Baseline in Clinical Global Impression Scale - Severity (CGI-S)

The Clinical Global Impression Scale-Severity is a clinician-rated scale to assess a patient's overall mental health. The scale ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).

Time frame:
Day 43
Reported as:
Least squares mean · score on a scale
Clinical From Baseline in Clinical Global Impression Scale - Severity (CGI-S)
score on a scaleLumateperone 42mgPlacebo
Clinical From Baseline in Clinical Global Impression Scale - Severity (CGI-S)-1.7 ± 0.07-1.1 ± 0.07
Statistical analysis
  • Lumateperone 42mg vs Placebo · Mixed Effects Model for Repeated Measure · p = <0.0001 · Least squares mean difference: -0.6 · 95% CI -0.82 to -0.44

Adverse events

Collected over From signing ICF until end of study procedures (~10 weeks), including 6 weeks of double-blind treatment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lumateperone 42mg0/240 (0%)0/240 (0%)84/240 (35%)
Placebo0/241 (0%)1/241 (0.4%)37/241 (15.4%)
Most frequent serious events
Most frequent serious events
EventLumateperone 42mgPlacebo
DermatitisSkin and subcutaneous tissue disorders0/2401/241
Most frequent other events
Most frequent other events
EventLumateperone 42mgPlacebo
HeadacheNervous system disorders37/24030/241
SomnolenceNervous system disorders31/2404/241
DizzinessNervous system disorders28/2404/241
NauseaGastrointestinal disorders19/2405/241

Baseline characteristics

Age, Continuous
Age, Continuous(years)Lumateperone 42mgPlaceboTotal
Mean42.9 ± 14.5443.4 ± 13.8943.2 ± 14.21
Sex: Female, Male
Sex: Female, Male(Participants)Lumateperone 42mgPlaceboTotal
Female150148298
Male9093183
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Lumateperone 42mgPlaceboTotal
Race — White205188393
Race — Black or African American324981
Race — Asian123
Race — Other213
Race — Multiple011
Region of Enrollment
Region of Enrollment(participants)Lumateperone 42mgPlaceboTotal
United States8278160
Ukraine201737
Bulgaria7592167
Serbia152439
Russia483078
Montgomery-Asberg Depression Rating Scale
Montgomery-Asberg Depression Rating Scale(units on a scale)Lumateperone 42mgPlaceboTotal
Combined MDD and Bipolar Depression Mixed Features Population31.3 ± 4.0531.1 ± 4.0731.3 ± 4.06
Bipolar Depression Mixed Features Population31.8 ± 4.4031.1 ± 4.0131.5 ± 4.22
MDD Mixed Features Population30.8 ± 3.5931.2 ± 4.1631.0 ± 3.88
Overall Population31.3 ± 4.3331.4 ± 4.3631.3 ± 4.34
08

Study locations

42 sites
  • Clinical Site
    Garden Grove, California 92845, United States
  • Clinical Site
    Oceanside, California 92056, United States
  • Clinical Site
    Sherman Oaks, California 91403, United States
  • Clinical Site
    Lauderhill, Florida 33319, United States
  • Clinical Site
    Miami, Florida 33122, United States
  • Clinical Site
    Orange City, Florida 32763, United States
  • Clinical Site
    Atlanta, Georgia 30331, United States
  • Clinical Site
    Decatur, Georgia 30030, United States
  • Clinical Site
    O'Fallon, Missouri 63368, United States
  • Clinical Site
    Cedarhurst, New York 11694, United States
  • Clinical Site
    New York, New York 10128, United States
  • Clinical Site
    Charlotte, North Carolina 28211, United States
  • Clinical Site
    Bellevue, Washington 98007, United States
  • Clinical Site
    Burgas, 8000, Bulgaria
  • Clinical Site
    Kardzhali, 6600, Bulgaria
  • Clinical Site
    Plovdiv, 4004, Bulgaria
  • Clinical Site
    Ruse, 7003, Bulgaria
  • Clinical Site
    Sofia, 1113, Bulgaria
  • Clinical Site
    Sofia, 1408, Bulgaria
  • Clinical Site
    Sofia, 1431, Bulgaria
  • Clinical Site
    Sofia, 1680, Bulgaria
  • Clinical Site
    Varna, 9020, Bulgaria
  • Clinical Site
    Veliko Tarnovo, 5000, Bulgaria
  • Clinical Site
    Vratsa, 3000, Bulgaria
  • Clinical Site
    Ekaterinburg, 620030, Russian Federation
  • Clinical Site
    Moscow, 105082, Russian Federation
  • Clinical Site
    Saint Petersburg, 190121, Russian Federation
  • Clinical Site
    Saint Petersburg, 192019, Russian Federation
  • Clinical Site
    Saint Petersburg, 195160, Russian Federation
  • Clinical Site
    Saint Petersburg, 197341, Russian Federation
  • Clinical Site
    Saint Petersburg, 199106, Russian Federation
  • Clinical Site
    Tomsk, 634009, Russian Federation
  • Clinical Site
    Belgrade, 11000, Serbia
  • Clinical Site
    Kovin, 26220, Serbia
  • Clinical Site
    Kragujevac, 34000, Serbia
  • Clinical Site
    Kyiv, 1133, Ukraine
  • Clinical Site
    Lviv, 79021, Ukraine
  • Clinical site
    Odesa, 65006, Ukraine
  • Clinical Site
    Odesa, 67513, Ukraine
  • Clinical Site
    Poltava, 36013, Ukraine
  • Clinical Site
    Smila, 20708, Ukraine
  • Clinical Site
    Vinnytsia, 21005, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2020 to primary completion in Nov 2022, 33 months.

Results were first posted in Mar 2025, 2 years 3 months after primary completion.

Of 29 industry-sponsored phase 3 interventional studies under Bipolar Disorder, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 49. This study's 33 months is close to that.

Counting every sponsor, half of 43 studies reached it within 37 months; a quarter within 21 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2020
First posted
Feb 26, 2020
StartActual
Feb 27, 2020
Primary completionActual
Nov 30, 2022
CompletionActual
Nov 30, 2022
Results first posted
Mar 19, 2025
Last update
Mar 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04285515
Responsible party
Sponsor
First posted
Feb 26, 2020
Start date
Feb 27, 2020
Primary completion
Nov 30, 2022
Completion
Nov 30, 2022
Results posted
Mar 19, 2025
Last update
Mar 19, 2025

Study contacts

Susan Kozauer, MD
study director · Intra-Cellular Therapies, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lumateperone

Start the discussion